HN1997000118A - 1,3, oxa thiolane nucleoside compuestos y composiciones - Google Patents

1,3, oxa thiolane nucleoside compuestos y composiciones

Info

Publication number
HN1997000118A
HN1997000118A HN1997000118A HN1997000118A HN1997000118A HN 1997000118 A HN1997000118 A HN 1997000118A HN 1997000118 A HN1997000118 A HN 1997000118A HN 1997000118 A HN1997000118 A HN 1997000118A HN 1997000118 A HN1997000118 A HN 1997000118A
Authority
HN
Honduras
Prior art keywords
compositions
nucleoside compounds
thiolane
oxa
oxa thiolane
Prior art date
Application number
HN1997000118A
Other languages
English (en)
Inventor
Shire Canada Inc
Original Assignee
Shire Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10699340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HN1997000118(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Canada Inc filed Critical Shire Canada Inc
Publication of HN1997000118A publication Critical patent/HN1997000118A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/167—Heterorings having sulfur atoms as ring heteroatoms, e.g. vitamin B1, thiamine nucleus and open chain analogs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/38—Nucleosides
    • C12P19/40—Nucleosides having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same ring, e.g. purine nucleosides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/001—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by metabolizing one of the enantiomers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/006—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by reactions involving C-N bonds, e.g. nitriles, amides, hydantoins, carbamates, lactames, transamination reactions, or keto group formation from racemic mixtures

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A 1,3, OXA THIOLANE NUCLEOSIDE COMPUESTOS Y COMPOSICIONES
HN1997000118A 1991-08-01 1997-08-18 1,3, oxa thiolane nucleoside compuestos y composiciones HN1997000118A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919116601A GB9116601D0 (en) 1991-08-01 1991-08-01 1,3-oxathiolane nucleoside analogues

Publications (1)

Publication Number Publication Date
HN1997000118A true HN1997000118A (es) 1999-11-12

Family

ID=10699340

Family Applications (1)

Application Number Title Priority Date Filing Date
HN1997000118A HN1997000118A (es) 1991-08-01 1997-08-18 1,3, oxa thiolane nucleoside compuestos y composiciones

Country Status (41)

Country Link
US (2) US5538975A (es)
EP (2) EP1155695B1 (es)
JP (1) JP2960778B2 (es)
KR (1) KR100242454B1 (es)
CN (5) CN1034810C (es)
AP (1) AP321A (es)
AT (2) ATE448787T1 (es)
AU (1) AU659668B2 (es)
BG (1) BG61693B1 (es)
CA (2) CA2682254C (es)
CZ (1) CZ283765B6 (es)
DE (2) DE69233776D1 (es)
DK (2) DK0526253T3 (es)
EE (1) EE03002B1 (es)
EG (1) EG20193A (es)
ES (2) ES2186667T3 (es)
FI (1) FI940435A (es)
GB (1) GB9116601D0 (es)
GE (1) GEP20002094B (es)
HK (2) HK1008672A1 (es)
HN (1) HN1997000118A (es)
HU (2) HUT70030A (es)
IL (1) IL102616A (es)
MA (1) MA22919A1 (es)
MD (1) MD1434C2 (es)
MX (1) MX9204474A (es)
NO (3) NO300842B1 (es)
NZ (1) NZ243637A (es)
OA (1) OA09883A (es)
PH (1) PH30983A (es)
PT (2) PT1155695E (es)
RS (1) RS49993B (es)
RU (1) RU2126405C1 (es)
SG (1) SG68541A1 (es)
SK (1) SK280131B6 (es)
TJ (1) TJ244R3 (es)
TN (1) TNSN92070A1 (es)
TW (2) TWI232217B (es)
WO (1) WO1993003027A1 (es)
YU (1) YU49259B (es)
ZA (1) ZA925668B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6346627B1 (en) 1990-02-01 2002-02-12 Emory University Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US6642245B1 (en) * 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US6812233B1 (en) * 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
GB9311709D0 (en) * 1993-06-07 1993-07-21 Iaf Biochem Int Stereoselective synthesis of nucleoside analogues using bicycle intermediate
CA2637774C (en) 1993-09-10 2011-07-19 Emory University Nucleosides with anti-hepatitis b virus activity
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) * 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
GB9506644D0 (en) * 1995-03-31 1995-05-24 Wellcome Found Preparation of nucleoside analogues
CA2219132C (en) 1995-06-07 2007-03-06 Emory University Nucleosides with anti-hepatitis b virus activity
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
EA001920B1 (ru) 1997-03-19 2001-10-22 Эмори Юниверсити Синтез 1,3-оксаселеноланнуклеозидов, их активность против вируса иммунодефицита человека и против вируса гепатита-b
US6410546B1 (en) 1997-04-07 2002-06-25 Triangle Pharmaceuticals, Inc. Use of MKC-442 in combination with other antiviral agents
ES2232169T3 (es) 1998-08-12 2005-05-16 Gilead Sciences, Inc. Procedimiento de fabricacion de nucleosidos de 1,3-oxatiolano.
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
IL142910A0 (en) 1998-11-02 2002-04-21 Triangle Pharmaceuticals Inc Combination therapy to treat hepatitis b virus
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
IL151981A0 (en) * 2000-03-29 2003-04-10 Univ Georgetown Method of treating hepatitis delta viral infection
CA2308559C (en) 2000-05-16 2005-07-26 Brantford Chemicals Inc. 1,3-oxathiolan-5-ones useful in the production of antiviral nucleoside analogues
AU2008202336B2 (en) * 2001-03-01 2011-11-10 Abbvie Inc. Polymorphic and other crystalline forms of cis-FTC
JP5105689B2 (ja) * 2001-03-01 2012-12-26 ギリード・サイエンシズ・インコーポレーテッド 多形型および他の結晶型のシス−ｆｔｃ
AU2002364160A1 (en) * 2001-12-14 2003-06-30 Pharmasset Ltd. Preparation of intermediates useful in the synthesis of antiviral nucleosides
CN105596356A (zh) 2003-01-14 2016-05-25 吉里德科学公司 用于联合抗病毒治疗的组合物和方法
ITMI20030578A1 (it) * 2003-03-24 2004-09-25 Clariant Lsm Italia Spa Processo ed intermedi per la preparazione di emtricitabina
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
CN100360528C (zh) * 2005-08-31 2008-01-09 四川大学 4-氨基-1-(2-羟甲基-1,3-氧硫杂环戊烷-5-基)-2(1h)-嘧啶酮的制备方法
WO2007077505A2 (en) * 2005-12-30 2007-07-12 Ranbaxy Laboratories Limited Crystalline l-menthyl (2r, 5s)-5-(4-amino-5-fluoro-2-oxo-2h-pyrimidin-1-yl)[1, 3]oxathiolan-2-carboxylate and process for preparation thereof
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2671888A1 (en) 2008-12-23 2013-12-11 Gilead Pharmasset LLC 3',5'-cyclic nucleoside phosphate analogues
MX2011006891A (es) 2008-12-23 2011-10-06 Pharmasset Inc Fosforamidatos de nucleosidos.
EA201100851A1 (ru) * 2008-12-23 2012-04-30 Фармассет, Инк. Аналоги нуклеозидов
EP2414507B1 (en) * 2009-04-03 2014-07-02 Medical Research Council Mutants of activation-induced cytidine deaminase (aid) and methods of use
EP2377862A1 (en) 2010-03-29 2011-10-19 Esteve Química, S.A. Process for obtaining emtricitabine
EP2552931B1 (en) 2010-03-31 2014-07-23 Gilead Pharmasset LLC Stereoselective synthesis of phosphorus containing actives
BR112014016966A8 (pt) 2012-01-10 2017-07-04 Cc Jensen As método e sistema para limpar óleo degradado
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
DE2950317A1 (de) * 1979-12-14 1981-06-19 Agfa-Gevaert Ag, 5090 Leverkusen Elektrothermographische vorrichtung
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
DK0674634T3 (da) * 1989-02-08 2003-08-04 Iaf Biochem Int Fremgangsmåde til fremstilling af substituerede 1,3-oxathiolaner med antivirale egenskaber
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
WO1992010496A1 (en) * 1990-12-05 1992-06-25 University Of Georgia Research Foundation, Inc. ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES
NZ241625A (en) * 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
ATE219366T1 (de) * 1991-03-06 2002-07-15 Univ Emory Verwendung von 5-fluoro-2'-deoxy-3'-thiacytidin zur behandlung von hepatitis b
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues

Also Published As

Publication number Publication date
CN1074924C (zh) 2001-11-21
PT526253E (pt) 2003-03-31
HU211333A9 (en) 1995-11-28
TJ244R3 (en) 1999-11-24
EP0526253B1 (en) 2002-11-13
RU2126405C1 (ru) 1999-02-20
CN101066970A (zh) 2007-11-07
TWI232217B (en) 2005-05-11
DE69232845D1 (de) 2002-12-19
GEP20002094B (en) 2000-05-10
DE69233776D1 (de) 2009-12-31
PH30983A (en) 1997-12-23
CN1132073A (zh) 1996-10-02
YU72303A (sh) 2006-05-25
EG20193A (en) 1997-10-30
CN101074228A (zh) 2007-11-21
AP9200414A0 (en) 1992-07-31
NO2005017I2 (no) 2007-10-01
BG61693B1 (bg) 1998-03-31
EE03002B1 (et) 1997-06-16
YU74992A (sh) 1995-12-04
KR100242454B1 (ko) 2000-03-02
NZ243637A (en) 1995-03-28
NO940322D0 (no) 1994-01-31
IL102616A (en) 1996-10-31
OA09883A (en) 1994-09-15
DK0526253T3 (da) 2003-03-17
JP2960778B2 (ja) 1999-10-12
CN1034810C (zh) 1997-05-07
SG68541A1 (en) 1999-11-16
NO2005017I1 (no) 2005-09-05
HK1038189A1 (en) 2002-03-08
CA2114221A1 (en) 1993-02-18
MD1434C2 (ro) 2000-12-31
US5618820A (en) 1997-04-08
EP1155695A1 (en) 2001-11-21
PT1155695E (pt) 2010-02-02
FI940435A0 (fi) 1994-01-28
MX9204474A (es) 1993-12-01
CN100542535C (zh) 2009-09-23
DK1155695T3 (da) 2010-04-06
ATE227720T1 (de) 2002-11-15
SK10494A3 (en) 1994-12-07
IL102616A0 (en) 1993-01-14
MD950114A (en) 1996-06-28
BG98616A (bg) 1995-03-31
EP1155695B1 (en) 2009-11-18
CZ283765B6 (cs) 1998-06-17
CA2682254A1 (en) 1993-02-18
TW366347B (en) 1999-08-11
HK1008672A1 (en) 1999-05-14
CA2682254C (en) 2012-02-21
NO940322L (no) 1994-03-21
SK280131B6 (sk) 1999-08-06
EP0526253A1 (en) 1993-02-03
ES2335968T3 (es) 2010-04-07
MA22919A1 (fr) 1993-04-01
CA2114221C (en) 2009-12-22
DE69232845T2 (de) 2003-04-24
HU9400285D0 (en) 1994-05-30
US5538975A (en) 1996-07-23
MD1434B2 (en) 2000-03-31
CZ20394A3 (en) 1994-07-13
HUT70030A (en) 1995-09-28
JPH07500317A (ja) 1995-01-12
CN1070191A (zh) 1993-03-24
FI940435A (fi) 1994-01-28
ZA925668B (en) 1993-04-28
RS49993B (sr) 2008-09-29
GB9116601D0 (en) 1991-09-18
NO300842B1 (no) 1997-08-04
NO2008009I1 (no) 2008-06-30
CN1302612A (zh) 2001-07-11
AP321A (en) 1994-02-28
AU659668B2 (en) 1995-05-25
WO1993003027A1 (en) 1993-02-18
ATE448787T1 (de) 2009-12-15
ES2186667T3 (es) 2003-05-16
TNSN92070A1 (fr) 1993-06-08
AU2340892A (en) 1993-03-02
YU49259B (sh) 2004-12-31

Similar Documents

Publication Publication Date Title
HN1997000118A (es) 1,3, oxa thiolane nucleoside compuestos y composiciones
HN1999000155A (es) 4-carboxiamino-2-metil-1,2,3,4-tetrahidroquinolinas
HN1998000036A (es) Compuesto de pirazina
HN1997000090A (es) Compuestos de piridilpirrol
DE69327678D1 (de) Positiv arbeitende Resistzusammensetzung
DE69229332D1 (de) Positiv-arbeitende Resistzusammensetzung
DE68903468T2 (de) Schmiermittelzusammensetzungen.
DE69220612D1 (de) Positivarbeitende Photoresistzusammensetzung
DE69226456T2 (de) Negativarbeitende Photoresistzusammensetzung
DE69028476D1 (de) Positive arbeitende Fotolackzusammensetzungen
ITMI920006A0 (it) Composizioni di lubrificanti
DE69309769D1 (de) Positivarbeitende Resistzusammensetzung
DE3861251D1 (de) Negative resistzusammensetzungen.
ES2056153T3 (es) Expectorante que comprende un derivado hidroxialquilcisteina.
AR241022A2 (es) "fosfatidos de eteres de glicerina y procedimiento para su preparacion"
HN1998000045A (es) Composiciones farmaceuticas
DE69209356D1 (de) Positiv-arbeitende Resistzusammensetzung
NO924361L (no) Formazan parasittiske midler
IT8323545A0 (it) Composizioni terapeutiche adattivita' antivirale.
DE69027139D1 (de) Zusammensetzungen
HN1998000102A (es) Composiciones solubilizadas de sertralina
DE69223083D1 (de) Positivarbeitende Resistzusammensetzung
IT9022104A0 (it) Composizioni per la terapia mucolitica
DE58904011D1 (de) Schmierstoffzusammensetzungen.
HN1997000013A (es) Compuestos 1,4 dihidropiridina